{
  "id": "mhgap#risk_safety_f020d1a0",
  "content": "y Benefits and potential harms need to be considered y Since the harms of the intervention outweigh the\nin the context of low certainty of evidence, to take benefits, a strong recommendation is made against\ninto account capacities to correctly identify children use of pharmacological interventions for children\nand adolescents with anxiety who may benefit from and adolescents with anxiety disorders.\npharmacological treatments and to monitor adverse\nRemarks\neffects and risk of suicidality in non-specialist\ny Diagnosis of anxiety in children can be influenced by\nsettings.\nthe cultural context and requires a comprehensive\ny There is very low certainty of evidence supporting\nassessment of determinants at a family level\nbenefits of SSRIs, as a group, in improving anxiety\nand in the environment to reduce risks of\nsymptoms and there is moderate-quality evidence\novermedicalization.\nsupporting treatment response to group SSRI.\nThe available evidence shows no significant\nResearch gaps\ndifference between both all TCAs (pooled) and\ny Additional evidence is required to establish the\nbenzodiazepines compared with pill placebo in\nbenefits and safety of prescribing pharmacological\nimproving anxiety symptoms.\ntreatment for anxiety in children and adolescents in\ny Group SSRIs and benzodiazepines had significantly\nnon-specialist settings.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "relationships",
      "risk_safety",
      "screening_cues",
      "referral",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety y Benefits and potential harms need to be considered y Since the harms of the intervention outweigh the\nin the context of low certainty of evidence, to take benefits, a strong recommendation is made against\ninto account capacities to correctly identify children use of pharmacological interventions for children\nand adolescents with anxiety who may benefit from and adolescents with anxiety disorders.\npharmacological treatments and to monitor adverse\nRemarks\neffects and risk of suicidality in non-specialist\ny Diagnosis of anxiety in children can be influenced by\nsettings.\nthe cultural context and requires a comprehensive\ny There is very low certainty of evidence supporting\nassessment of determinants at a family level\nbenefits of SSRIs, as a group, in improving anxiety\nand in the environment to reduce risks of\nsymptoms and there is moderate-quality evidence\novermedicalization.\nsupporting treatment response to group SSRI.\nThe available evidence shows no significant\nResearch gaps\ndifference between both all TCAs (pooled) and\ny Additional evidence is required to establish the\nbenzodiazepines compared with pill placebo in\nbenefits and safety of prescribing pharmacological\nimproving anxiety symptoms.\ntreatment for anxiety in children and adolescents in\ny Group SSRIs and benzodiazepines had significantly\nnon-specialist settings. Y benefits and potential harms need to be considered y since the harms of the intervention outweigh the\nin the context of low certainty of evidence, to take benefits, a strong recommendation is made against\ninto account ..."
}